The life science industry is all hands on deck in the race to develop vaccines, therapies and diagnostics in the fight against coronavirus. But while some prosper, many in the sector are forced to halt clinical trials and mothball labs
Investment in later stage clinical development is needed to back up recent improvements in the discovery of new antibiotics, and to ensure the use of novel products is managed to maintain their effectiveness
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.